Evaluating the Efficacy of First-Person Perspective Simulation Video for Non-Technical Skill Training in Airway Management during Clinical Clerkship. - Evaluating the Efficacy of First-Person Perspective Simulation Video for Non-Technical Skill Training in Airway Management during Clinical Clerkship.

开始日期2024-01-31

申办/合作机构

Akita University

JPRN-UMIN000053148 / RecruitingIIT

Verification of the Effectiveness of Digital Transformation (Dx) in Nursing Homes to Improve the Nursing Care Environment - Verification of the Effectiveness of Digital Transformation (Dx) in Nursing Homes

开始日期2024-01-15

申办/合作机构

Akita University

JPRN-UMIN000053128 / SuspendedIIT

Intraoperative renal desaturation and postoperative acute kidney injury in patients undergoing robot-assisted laparoscopic radical prostatectomy - Intraoperative renal desaturation and postoperative acute kidney injury in patients undergoing robot-assisted laparoscopic radical prostatectomy

开始日期2024-01-01

申办/合作机构

Akita University

100 项与 Akita University 相关的临床结果

登录后查看更多信息

0 项与 Akita University 相关的专利（医药）

登录后查看更多信息

11,662

项与 Akita University 相关的文献（医药）

2024-12-18·JOURNAL OF PHYSICS-CONDENSED MATTER

Study of quantum nonlocality by CHSH function and its extension in disordered fermions

Article

作者: Kuno, Yoshihito

Abstract:

Quantum nonlocality is an important concept in quantum physics. In this work, we study the quantum nonlocality in a fermion many-body system under quasi-periodic disorders. The Clauser–Horne–Shimony–Holt (CHSH) inequality is systematically investigated, which quantifies quantum nonlocality between two sites. We find particular behaviors of the quantifiers of quantum nonlocality around the extended and critical phase transitions in the system and further that the CHSH inequality is not broken in the globally averaged picture of the maximum value of the quantum nonlocality, but the violation probability of the CHSH inequality for two site pairs in the system becomes sufficiently finite in the critical phase and on a critical phase boundary. Further, we investigate an extension of the CHSH inequality, Mermin–Klyshko–Svetlichny (MKS) polynomials, which can characterize multipartite quantum nonlocality. We also find a similar behavior to the case of CHSH inequality. In particular, in the critical regime and on a transition point, the adjacent three-qubit MKS polynomial in a portion of the system exhibits a quantum nonlocal violation regime with a finite probability in the critical phase.

2024-12-01·JOURNAL OF LUMINESCENCE

Scintillation and dosimeter properties of Tb-doped strontium fluoride transparent ceramics

作者: Ichiba, Kensei ; Conner, Robin L. ; Jacobsohn, Luiz G. ; Nakauchi, Daisuke ; Yanagida, Takayuki ; Kawano, Naoki ; Kato, Takumi ; Okazaki, Kai ; Takebuchi, Yuma

Luminescence properties of strontium fluoride transparent ceramics with various TbF₃ amounts (0.1, 0.5, and 1 %) were investigated.Scintillation peaks derived from the electronic transitions between 4f levels in Tb³⁺ were observedThe observed scintillation decay times of approx. 8.3 ms were typical for the electronic transitions in Tb³⁺.Furthermore, the Tb-doped strontium fluoride transparent ceramics showed thermoluminescence and optically stimulated luminescence (OSL) with Tb³⁺ serving as the recombination center.The most intense thermoluminescence signal was detected from the 0.1 % Tb-doped transparent ceramic within the range of 0.01-100 mGy.OSL stimulated by 600 nm light of the same material was the most intense, and its lowest detectable limit was about 100 mGy.

2024-11-01·BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

FoxD1 expression identifies a distinct subset of hepatic stellate cells involved in liver fibrosis

Article

作者: Tatematsu, Megumi ; Morii, Mayako ; Mizuno, Masaru ; Fuchimukai, Akane ; Yamagata, Kenki ; Takasuga, Shunsuke ; Yamada, Toshiki ; Ebihara, Takashi

Hepatic stellate cells (HSCs) are pericytes of the liver responsible for liver fibrosis and cirrhosis, which are the end stages of chronic liver diseases. TGF-β activates HSCs, leading to the differentiation of myofibroblasts in the process of liver fibrosis. While the heterogeneity of HSCs is appreciated in the fibrotic liver, it remains elusive which HSC subsets mainly contribute to fibrosis. Here, we show that the expression of the pericyte marker FoxD1 specifically marks a subset of HSCs in FoxD1-fate tracer mice. HSCs fate-mapped by FoxD1 were preferentially localized in the portal and peripheral areas of both the homeostatic and fibrotic liver induced by carbon tetrachloride. Furthermore, the deletion of Cbfβ, which is necessary for TGF-β signaling, in FoxD1-expressing cells ameliorated liver fibrosis. Thus, we identified an HSC subset that preferentially responds to liver injuries.

项与 Akita University 相关的新闻（医药）

2024-09-25

·PRNewswire

Akita Biosciences Unveils Groundbreaking Peer-Reviewed Data on Innovative Nasal Spray Technology

BOSTON and COLUMBUS, Ohio, Sept. 25, 2024 /PRNewswire/ -- Akita Biosciences, Inc., a biotech company that develops innovative nasal spray formulations for drug, device, and cosmetic applications, announces the publication of its platform nasal technology in the prestigious scientific journal Advanced Materials. Akita Biosciences is currently marketing Profi Nasal Spray as a cosmetic product for nasal hygiene, and this study reports extensive pre-clinical studies with potential drug and medical device applications. Continue Reading Pathogens in respiratory droplets often adhere to the nasal lining, leading to infections. Akita Biosciences' Pathogen Capture and Neutralization Spray (PCANS) technology is designed to coat the nasal passages with a gel-like barrier lasting several hours. In pre-clinical studies, it has been shown to capture large respiratory droplets, block a broad spectrum of viruses and bacteria, and neutralize them effectively. Courtesy of Randal McKenzie, McKenzie Illustrations. The peer-reviewed study, 'Toward a Radically Simple Multi-Modal Nasal Spray for Preventing Respiratory Infections,' highlights Akita Biosciences' innovative approach to respiratory protection. The company's Pathogen Capture and Neutralization Spray (PCANS) technology demonstrates broad-spectrum activity against common pathogens, including viruses such as influenza, SARS-CoV-2, RSV, adenovirus, and the bacterium Klebsiella pneumoniae, all of which can spread through airborne transmission and pose significant health risks. Developed by researchers at Brigham and Women's Hospital, this innovative technology is designed to form a gel-like barrier in the nasal passages to capture, block, and neutralize these pathogens for several hours. "We know that influenza, COVID-19, and other seasonal infections cause thousands of deaths and make hundreds of thousands seriously ill every year. In our research, we looked at how a nasal spray we developed might protect against these respiratory viruses," said Dr. Jeff Karp, co-founder of Akita Biosciences, Distinguished Chair and Professor at Brigham and Women's Hospital, and co-senior author of this work. "Our pre-clinical findings indicate that this nasal spray can create a robust barrier that effectively captures airborne viruses and bacteria, preventing their transport across the nasal lining, and rapidly neutralizing them." Vulnerable populations—including children, the elderly, immunocompromised individuals, and those with chronic respiratory conditions—are at heightened risk of severe infections and complications. The World Health Organization recently updated its definitions to highlight that many respiratory infections primarily spread through airborne transmission, making them difficult to avoid. Environments such as schools, airplanes, nursing homes, and other crowded spaces present significant challenges for breaking the chain of transmission due to shared air, close contact, and prolonged exposure. PCANS is designed to combat these issues by shielding the nasal passages, the primary entry point for many airborne pathogens. "The nasal spray was developed using ingredients from the FDA's Inactive Ingredient Database (IID), which have been previously used in approved nasal sprays or long used in consumer products," said Dr. Nitin Joshi, co-founder of Akita Biosciences, Assistant Professor at Brigham and Women's Hospital, and co-senior author of the paper. "The formulation has been engineered to offer broad-spectrum protection and stay in the nasal passages for over eight hours, setting a new standard for how long nasal sprays last." "We're honored that our technology has been recognized by such a prestigious journal," said Alex Revelos, CEO and co-founder of Akita Biosciences. "Our mission is to deliver nasal therapies that protect against airborne threats and empower people to take control of their health." About Akita Biosciences, Inc. Akita Biosciences is at the forefront of health and wellness with innovative nasal sprays that leverage world-class science and advanced formulations to enhance human health. While traditional supplements focus on general wellness, our approach targets the nasal passages—where airborne germs, allergens, and irritants first enter the body. By delivering proactive, targeted solutions at this crucial point of entry, we support respiratory health and contribute to overall well-being. At Akita, we're not just addressing health challenges; we're setting a new standard for how people support their health in an increasingly airborne world. Discover how we are shaping the future at and . Media Contact: Michael Simonson (201) 572-1030 [email protected] SOURCE Akita Biosciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED